19例新型冠状病毒肺炎患者用药分析

Medication Status of 19 Patients with Coronavirus Disease 2019

目的基于真实世界分析某院新型冠状病毒肺炎(COVID-19)确诊患者的临床用药,为临床合理用药提供建议。方法根据国家卫生健康委员会《新型冠状病毒肺炎诊疗方案(试行第七版)》推荐用药,对医院2020年1月30日至3月1日收治的19例COVID-19患者开展用药分析。结果确诊患者中,男女比例相当,年龄以30~50岁为主,多为亲属间传播,临床分型多为普通型;42.11%的患者入院前曾用药治疗,入院后多接受两联抗病毒药物治疗,其余对症治疗药物包括抗菌药物(47.37%)、呼吸系统药物(63.16%)、消化系统药物(10.53%)、保肝药物(36.84%)、抗焦虑药物(26.32%)、免疫调节药物(42.11%),中药注射剂和中药汤剂同时联用率为89.47%;47.37%的患者发生药品不良反应,主要原因为用药时间过长、联合用药不适宜、遴选药品不适宜等。结论19例COVID-19患者用药基本符合现行诊疗方案,但部分存在不合理用药现象,需规范临床用药,加强用药监护。

Objective To analyze the clinical medication of patients with the coronavirus disease 2019(COVID-19)in a hospital based on the real world,and provide suggestions for clinical rational use of drugs.Methods According to the drugs recommended in the Diagnosis and Treatment Plan for the COVID-19(Trial Version 7)released by the National Health Commission(NHC),the medication analysis was carried out on 19 patients with the COVID-19 admitted to the hospital from January 30th,2020 to March 1st,2020.Results Among the diagnosed patients,the proportion of male and female was equal,mainly in the population with 30-50 years old,most of them were spread among relatives,and their clinical classification mainly showed common type.42.11%of the patients had taken medication before admission,and most received two-suite antiviral drugs after admission,the other symptomatic drugs included antibiotics(47.37%),respiratory system drugs(63.16%),digestive system drugs(10.53%),l iver protection drugs(36.84%),anti-anxiety drugs(26.32%),immunomodulatory drugs(42.11%),t he combined use rate of traditional Chinese medicine(TCM)injection and TCM decoction was 89.47%.47.37%of the patients had adverse drug reactions,mainly due to the too long medication time,inappropriate combination of medication,inappropriate selection of drugs and so on.Conclusion The medication of 19 patients with COVID-19 basically conforms to the current diagnosis and treatment plan,but some patients have irrational medication.Therefore it is necessary to standardize clinical medication and strengthen medication monitoring.